Search Medical Condition
Please enter condition
Please choose location

Yong-Kang City, Taiwan Clinical Trials

A listing of Yong-Kang City, Taiwan clinical trials actively recruiting patients volunteers.

RESULTS

Found (75) clinical trials

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

This is an open-label (all people know the identity of the intervention), multicenter (when more than one hospital or medical school team work on a medical research study), 2 parts (First, dose escalation Phase and second, dose expansion Phase) study to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical responses of ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib) A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor In Asian Participants With Advanced Non-Small-Cell Lung Cancer Urothelial Cancer Esophageal Cancer Or Cholangiocarcinoma

This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esophageal cancer and cholangiocarcinoma.

Phase

0.0 miles

Learn More »

Study Of Diabetic Nephropathy With Atrasentan

The study objective is to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine or the onset of end stage renal disease (ESRD) in subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose (MTLDD) of a ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of LCZ696 Compared to Valsartan on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

The purpose of this study is to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.

Phase

0.0 miles

Learn More »

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin

Phase

0.0 miles

Learn More »

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort Turbuhaler in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort® Turbuhaler® in terms of pulmonary function, as well as to assess its safety.

Phase

0.0 miles

Learn More »

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Study is to evaluate if ART-123 given to patients who have severe sepsis complicated by at least one organ dysfunction and coagulopathy can decrease mortality.

Phase

0.0 miles

Learn More »

a Phase II Study in Primary Central Nervous System Lymphoma

5 PATIENT SELECTION 5.1 Eligibility Criteria Patients must fulfill all the following criteria to be eligible for admission for the study: 1. Histologically proven central nervous system lymphoma of brain parenchyma with or without leptomeningeal involvement. 2. No evidence of systemic lymphoma. 3. Age between 18 years and 75 years. ...

Phase

2.72 miles

Learn More »

Mucopolysaccharidosis I (MPS I) Registry

The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: - In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com - In Europe - +31-35-699-1232, europe@mpsiregistry.com - In Latin America - +617-591-5500, help@mpsiregistry.com - In North America - +617-591-5500, ...

Phase N/A

2.72 miles

Learn More »